Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

939 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
OX40 is a potent immune-stimulating target in late-stage cancer patients.
Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA, Moudgil T, Miller W, Haley D, Coffey T, Fisher B, Delanty-Miller L, Rymarchyk N, Kelly T, Crocenzi T, Bernstein E, Sanborn R, Urba WJ, Weinberg AD. Curti BD, et al. Among authors: bernstein e. Cancer Res. 2013 Dec 15;73(24):7189-7198. doi: 10.1158/0008-5472.CAN-12-4174. Epub 2013 Oct 31. Cancer Res. 2013. PMID: 24177180 Free PMC article. Clinical Trial.
A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
Clément-Duchêne C, Natale RB, Jahan T, Krupitskaya Y, Osarogiagbon R, Sanborn RE, Bernstein ED, Dudek AZ, Latz JE, Shi P, Wakelee HA. Clément-Duchêne C, et al. Among authors: bernstein ed. Lung Cancer. 2012 Oct;78(1):57-62. doi: 10.1016/j.lungcan.2012.06.003. Epub 2012 Jul 17. Lung Cancer. 2012. PMID: 22809813 Free article. Clinical Trial.
Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial.
Yamazaki T, Gunderson AJ, Gilchrist M, Whiteford M, Kiely MX, Hayman A, O'Brien D, Ahmad R, Manchio JV, Fox N, McCarty K, Phillips M, Brosnan E, Vaccaro G, Li R, Simon M, Bernstein E, McCormick M, Yamasaki L, Wu Y, Drokin A, Carnahan T, To Y, Redmond WL, Lee B, Louie J, Hansen E, Solhjem MC, Cramer J, Urba WJ, Gough MJ, Crittenden MR, Young KH. Yamazaki T, et al. Among authors: bernstein e. Lancet Oncol. 2022 Sep;23(9):1189-1200. doi: 10.1016/S1470-2045(22)00446-6. Epub 2022 Aug 8. Lancet Oncol. 2022. PMID: 35952709 Clinical Trial.
Peroxisome proliferator-activated receptor alpha is essential factor in enhanced macrophage immune function induced by angiotensin converting enzyme.
Saito S, Cao D, Bernstein EA, Jones AE, Rios A, Hoshi AO, Stotland AB, Nishi EE, Shibata T, Ahmed F, Van Eyk JE, Divakaruni A, Khan Z, Bernstein KE. Saito S, et al. Among authors: bernstein ea. Res Sq [Preprint]. 2024 Apr 22:rs.3.rs-4255086. doi: 10.21203/rs.3.rs-4255086/v1. Res Sq. 2024. PMID: 38746124 Free PMC article. Preprint.
939 results